Prescription medication · Vitamin D Analog (Topical)
calcipotriene
Also sold as Dovonex. This ointment treats plaque psoriasis.
Data updated 2026-05-15
- 3,344
- FDA reportsLightly reported
- $1.09
- Generic price (NADAC)
calcipotriene (Dovonex) is a prescription Vitamin D Analog (Topical). This ointment treats plaque psoriasis.
Calcipotriene and Betamethasone Dipropionate Ointment is a medicine that contains a vitamin D-like drug and a steroid. It is used on the skin to treat plaque psoriasis.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$1.09/unit
Generic Available
Yes (6 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
NADAC price trail: CALCIPOTRIENE 0.005% CREAM
Same CMS presentation as the headline generic unit price above (3 effective dates). Adjacent % compares consecutive NADAC releases for this description only, not a patient out-of-pocket quote. Latest step: -0.2% vs prior release.
| Effective | NADAC / unit | vs prior | NDCs |
|---|---|---|---|
| May 22, 2024 | $1.19/GM | - | 1 |
| September 18, 2024 | $1.10/GM | -7.6% | 1 |
| December 18, 2024 | $1.10/GM | -0.2% | 6 |
What it does
This ointment treats plaque psoriasis.
Common side effects
Itching, Scaly rash
Key warnings
This medicine can cause high calcium levels in your blood or urine.
The sections below are summarized in plain English from calcipotriene's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
This medicine has two active ingredients. Calcipotriene is similar to vitamin D and slows skin cell growth. Betamethasone dipropionate is a steroid that reduces swelling and itching.
Side Effects (from patient reports)
Based on 3,344 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for calcipotriene, by number of reports
- Psoriasis
Psoriasis
720 reports
- Diarrhoea 210
Diarrhoea
210 reports
- Arthralgia 199
Arthralgia
199 reports
- Rash 192
Rash
192 reports
- Nausea 180
Nausea
180 reports
- Pruritus 170
Pruritus
170 reports
- Pain 168
Pain
168 reports
- Headache 157
Headache
157 reports
- Therapeutic Product Effect Incomplete 145
Therapeutic Product Effect Incomplete
145 reports
- Fatigue 141
Fatigue
141 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for calcipotriene each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where calcipotriene sits
calcipotriene has more FDA adverse-event reports than 20% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is calcipotriene; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 3,344 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
3,344
Reports Mentioning Death
58
1.7% of reports — not proof of cause
Hospitalization Reports
440
Top Indication
Psoriasis
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | PSORIASIS | 720 |
| 3 | DIARRHOEA | 210 |
| 4 | ARTHRALGIA | 199 |
| 5 | RASH | 192 |
| 6 | NAUSEA | 180 |
| 7 | PRURITUS | 170 |
| 8 | PAIN | 168 |
| 9 | HEADACHE | 157 |
| 12 | THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 145 |
| 13 | FATIGUE | 141 |
| 14 | PSORIATIC ARTHROPATHY | 134 |
| 16 | SKIN EXFOLIATION | 119 |
| 17 | TREATMENT FAILURE | 117 |
| 18 | ABDOMINAL DISCOMFORT | 104 |
| 19 | ERYTHEMA | 91 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
This medicine can cause high calcium levels in your blood or urine. If this happens, stop treatment until your calcium levels are normal. This medicine can also affect your adrenal glands. This could lead to the need for steroid medicine. This medicine may increase your risk of cataracts and glaucoma. If you have vision problems, see an eye doctor.
Common Questions
How long should I use this ointment?
Can I use a bandage over the treated area?
Can I use this on my face?
What should I do if my skin gets irritated?
Can I use other psoriasis treatments with this ointment?
What should I do if I accidentally swallow this ointment?
Can children use this medicine?
What if I don't see improvement after 4 weeks?
Can this ointment affect my other health conditions?
Is it okay to share this medicine with someone else?
What are the common side effects of calcipotriene?
What drug class is calcipotriene?
What pregnancy or breastfeeding source fields are listed for calcipotriene?
Related Medications in Vitamin D Analog (Topical)
Other drugs grouped near calcipotriene - same-class peers and common alternatives.
adapalene
Differin
Compare with calcipotriene →
apremilast
Otezla
Apremilast (Otezla/Otezla XR) is a medicine that can help adults and children manage psoriatic arthritis and psoriasis.
Compare with calcipotriene →
azelaic acid
Finacea, Azelex
Azelaic acid gel is a topical medicine that helps treat rosacea.
Compare with calcipotriene →
benzoyl peroxide
Benzac, PanOxyl
Benzoyl peroxide is a topical medicine that fights germs on your skin.
Compare with calcipotriene →
betamethasone
Diprosone, Luxiq
Betamethasone dipropionate cream is a strong steroid medicine used on the skin.
Compare with calcipotriene →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for calcipotriene: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 3,344.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 1.73%.
- estradiol Δ 0.04 pts · 83,781 reports · Estrogen Hormone 1.77%death share
- semaglutide Δ 0.05 pts · 72,117 reports · GLP-1 Receptor Agonist 1.68%death share
- lifitegrast Δ 0.06 pts · 15,783 reports · LFA-1 Antagonist (Ophthalmic) 1.79%death share
- dulaglutide Δ 0.11 pts · 85,635 reports · GLP-1 Receptor Agonist 1.85%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on calcipotriene
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for calcipotriene
The FDA label for calcipotriene (sold under brand names such as Dovonex) classifies it as a prescription-only medication in the Vitamin D Analog (Topical) class. This ointment treats plaque psoriasis. Official labeling lists 2 commonly reported side effects, including Itching, Scaly rash.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 3,344 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS shows a generic unit cost of $1.09.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: December 7, 2023
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages